NCT01847313View on ClinicalTrials.gov

The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Diabetic Kidney Disease
Interventions
DRUG

Liraglutide

Daily administration of liraglutide for 6 months

Trial Locations (1)

Dublin 4

St Vincent's Healthcare Group, Dublin

All Listed Sponsors
collaborator

University College Dublin

OTHER

lead

Karl Neff

OTHER

NCT01847313 - The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease | Biotech Hunter | Biotech Hunter